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SCFAs strongly stimulate 
PYY production in human 
enteroendocrine cells
P. Larraufie  1, C. Martin-Gallausiaux2,3, N. Lapaque2, J. Dore2,4, F. M. Gribble1, F. Reimann1 & 
H. M. Blottiere  2,4
Peptide-YY (PYY) and Glucagon-Like Peptide-1 (GLP-1) play important roles in the regulation of food 
intake and insulin secretion, and are of translational interest in the field of obesity and diabetes. PYY 
production is highest in enteroendocrine cells located in the distal intestine, mirroring the sites where 
high concentrations of short chain fatty acids (SCFAs) are produced by gut microbiota. We show here 
that propionate and butyrate strongly increased expression of PYY but not GCG in human cell line and 
intestinal primary culture models. The effect was predominantly attributable to the histone deacetylase 
inhibitory activity of SCFA and minor, but significant contributions of FFA2 (GPR43). Consistent with the 
SCFA-dependent elevation of PYY gene expression, we also observed increased basal and stimulated 
PYY hormone secretion. Interestingly, the transcriptional stimulation of PYY was specific to human-
derived cell models and not reproduced in murine primary cultures. This is likely due to substantial 
differences in PYY gene structure between mouse and human. In summary, this study revealed a strong 
regulation of PYY production by SCFA that was evident in humans but not mice, and suggests that high 
fibre diets elevate plasma concentrations of the anorexigenic hormone PYY, both by targeting gene 
expression and hormone secretion.
The gut represents one the most important endocrine organs, secreting more than 20 different hormones from a 
scarce and heterogeneous enteroendocrine cell (EEC) population. Among these hormones, Peptide-YY (PYY) 
and Glucagon-like-peptide-1 (GLP-1) are of specific interest in the field of obesity and diabetes as they have been 
implicated in the regulation of food intake and insulin secretion, even though their precise physiological signifi-
cance in healthy and pathological states is still debated1–6. Moreover, these two peptides are co-secreted from the 
same subpopulation of EECs, commonly referred to as L-cells7.
Many studies have focused on the regulation of secretion by these cells, but studies into the mechanisms 
controlling the production of the prohormones have been limited7,8. In humans, PYY is mainly produced in the 
colon, where short chain fatty acids (SCFAs) are produced at high levels through the fermentation of fibre by gut 
microbiota9. SCFAs exert a number of actions on host cells, as they serve as energy substrates, signalling mole-
cules through specific G-protein coupled receptors FFA2, FFA3 and GPR109a, as well as intracellular signalling 
molecules inhibiting Lysine/Histone Deacetylase (HDACs)10–13. Human FFA2 and FFA3 have slightly different 
preferences for SCFAs. Both receptors have affinities in the order of 0.1 mM for propionate and butyrate, whereas 
for acetate the affinities are ~0.1 mM for FFA2 and >1 mM for FFA314,15. HDAC inhibition by butyrate is known 
to regulate the expression of a number of genes in different tissues and cell lines, and its function is mainly 
dependent on SP1/SP3 binding sites and independent of surface membrane SCFA receptors16–18.
High SCFA concentrations have been associated with elevated plasma levels of PYY and GLP-1 in humans 
and mice, mainly after consumption of digestion-resistant fibre diets resulting in increased colonic fermenta-
tion19–21. Two main mechanisms have been described to date: an acute effect of SCFAs on hormone secretion 
through activation of the Gq coupled receptor FFA222–24; and an increased number of EECs, particularly GLP-1 
and PYY expressing cells25–27. Zhou and collaborators also proposed that SCFAs may directly regulate Pyy and 
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Gcg (encoding Proglucagon) gene expression in rats, but limited their experiments to short periods of time and 
did not take into account a potential increased number of EECs resulting in apparent increased tissue content28. 
Most of the functional studies were performed in rodent models, while validation in humans is still lacking or did 
only observe acute stimulation at high, possibly supraphysiological, concentrations29. This may be explained by 
the differences in receptor expression between human and mouse L-cells, as human L-cells express much lower 
levels of FFAR3 than FFAR230, or by the different affinities of the two receptors for SCFAs. Compared with their 
human counterparts, mouse FFA2 has a lower affinity for SCFAs by 0.5–1 orders of magnitude whereas mouse 
FFA3 has a higher affinity for acetate and propionate, but similar affinity for butyrate15. These differences are not 
predicted to affect SCFA sensing in the colon where the concentrations are several orders of magnitude higher, 
but could explain differences in the detection of circulating SCFAs which are in the 10–100 μM range15. However, 
as SCFAs seem capable to alter PYY and GLP-1 plasma levels in humans29, other mechanisms may be involved 
and need to be assessed.
Results
NCI-h716 and HuTu-80 as EEC models for assessing SCFA responses. Studies on human EECs 
have been limited due to the scarcity of the cellular population, the absence of external markers and the limited 
models available. We used two cell lines modelling human GLP-1 secreting EECs, namely NCI-h716 and HuTu-
80, derived respectively from a human cecum adenocarcinoma and a duodenum adenocarcinoma31,32, to assess 
effects of SCFAs on prohormone gene expression. We validated the expression of different enteroendocrine mark-
ers in these cell lines, and confirmed the expression of PYY and GCG (PROGLUCAGON) in both cell lines, even 
though PYY expression was low (Fig. 1a). These two cell lines also expressed different levels of SCFA receptors 
and transporters, with the NCI-h716 cell line being the most similar to colonic GLP1-expressing-cells with a 
higher expression of FFAR2.
Effect of SCFAs on PYY and GCG gene expression. Incubation of NCI-h716 cells with SCFAs (each 
at a concentration of 2 mM, which is above the EC50 of both receptors and known to induce HDAC inhibi-
tion in different models) for 24 h increased PYY expression to different extents depending on the SCFA chain 
length (Fig. 1b). Butyrate was the most effective activator, increasing gene expression ~120-fold. Propionate 
had a smaller but still very strong effect, increasing expression ~40-fold, whereas the effect of acetate was more 
modest, increasing expression only ~2-fold. This effect was specific for PYY as propionate and butyrate slightly 
decreased GCG expression. Moreover, the effect of butyrate was time and dose dependent; we could not reach 
saturation in the dose or time range, due to negative effects on cell viability with more prolonged incubations or 
elevated concentrations (Fig. 1d,e). HuTu-80 cells yielded qualitatively similar results for PYY-specific transcrip-
tional up-regulation, although compared with NCI-h716 cells the fold increases in PYY expression were lower 
for butyrate (~16-fold increase) and propionate (~2-fold increase), and no significant change was observed with 
acetate (Fig. 1c).
Mechanisms involved in the effects of SCFAs. In vivo, SCFAs have been shown to alter EEC differ-
entiation and to increase their number. We therefore tested whether the effect of butyrate could be explained 
by a change of transcription factor expression. We could not detect any significant change in the expression of 
NEUROGENIN3, FOXA1, PAX4 or PAX6, which have previously been implicated in EEC differentiation towards 
GCG expression25,26 (Fig. 2a).
Human cells could respond to SCFAs at the concentration tested through two main mechanisms: activa-
tion of specific G-protein coupled receptors (FFA2, FFA3 and GPR109a) and inhibition of histone deacetylases 
(HDACs). To test the roles of these receptors, we first used selective agonists. Only the FFA2 agonist, tiglic acid, 
but not FFA3 or GPR109a agonists (1-methylcyclopropane carboxylate (1-MCPC) and niacin, respectively), 
induced a significant increase of PYY expression, which was of similar magnitude to acetate (Fig. 2b). Activation 
by PMA of PKC, which is downstream in the Gq pathway, also enhanced PYY expression, supporting the poten-
tial involvement of the Gq/PKC pathway in the response to FFA2 activation, in line with this pathway also mediat-
ing the acute effects of FFA2 activation on GLP-1 secretion33.To further investigate the role of FFA2 in NCI-h716 
cells, we depleted the receptor using Crispr/Cas9. Depletion of FFA2 was validated at the functional level, and 
we also confirmed that FFA2 depletion did not alter the FFAR3 gene sequence or its expression (Supplementary 
Figure 1). In FFA2-depleted cells, acetate or receptor agonists no longer induced any increase of PYY expression, 
whereas propionate and butyrate still induced strong responses, although diminished approximately 2-fold com-
pared with control cells (Fig. 2c). Interestingly, acetate did not induce any effect on PYY expression in HuTu-80 
cells, which endogenously express relatively low FFAR2 levels, but over-expression of FFAR2 was sufficient to 
induce increased PYY expression after acetate incubation, confirming a role for FFA2 in the response to acetate 
(Fig. 2d). We therefore concluded that the main effect of butyrate and propionate is not due to activation of the 
known G-protein coupled SCFA receptors.
We then used Trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA), which 
like butyrate and propionate, inhibit class I and II HDACs16,34,35. All three agents induced a similar strong effect 
on PYY expression in NCI-h716 cells (Fig. 2b). These results suggested that K/HDAC inhibition, an extensively 
described GPCR-independent activity of butyrate and propionate, underlies the observed strong increase of PYY 
expression. Taken together, these results suggested that SCFAs modulated PYY expression by two different but 
additive pathways: stimulation of FFA2 by all three SCFAs induced a small increase in PYY mRNA levels, whereas 
HDAC inhibition by propionate and butyrate induced a very large increase in PYY mRNA levels.
Increased PYY gene expression after butyrate or TSA treatment translated into elevated PYY secretion. 
Compared to controls, NCI-h716 cells incubated for 24 h with butyrate or TSA secreted four times more PYY 
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when subsequently incubated for 2 h in a buffer lacking secretory stimuli. By contrast, GLP-1 secretion was 
unchanged by the preincubations, mirroring the results found at the gene expression level (Fig. 2e).
Figure 1. SCFAs increase PYY expression in human EEC model cell lines. (a) Expression of EEC markers, 
SCFA transporters and receptors and specific enteroendocrine differentiation factors in NCI-h716 (dark grey) 
and HuTu-80 (light grey) were detected by RT-qPCR. Data are expressed relative to β-actin determined by the 
2−ΔCt method, on at least 4 distinct experiments performed in duplicate, represented as means ± s.e.m. N.D.: 
Not Detected. (b,c) Relative expression to control of PYY (dark grey) and GCG (light grey) after treatment with 
SCFAs (2 mM, 24 h) on NCI-h716 cells (b) and HuTu-80 cells (c). (d,e) Effect of concentration (d) or time of 
incubation (e) of butyrate on PYY expression in NCI-h716 cells. PYY expression relative to control expression is 
determined by the 2−ΔΔCt method using β-actin as control gene. Data are means ± s.e.m. of at least three distinct 
experiments. (***P < 0.001; **P < 0.01; *P < 0.05, Dunn to control test).
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Figure 2. Mechanisms involved in response to SCFAs. (a) Expression relative to control of PYY-producing EEC 
characteristic transcription factors after incubation with 2 mM butyrate for 24 h in NCI-h716 cells. (b) Effect of 
24 h incubation with SCFAs, receptor agonists, tiglic acid (FFA2, 100 μM), 1-MCPC (FFA3, 100 μM) and niacin 
(GPR109a, 1 mM), PMA (200 nM), TSA (500 nM), Valproic acid (5 mM) or SAHA (5 μM) on PYY expression 
in NCI-h716 cells. (c) Effect of 24 h incubation with SCFAs and receptor agonists on PYY expression in FFA2 
depleted NCI-h716 cells. (d) Expression of PYY relative to untreated cells in response to acetate (2 mM), tiglic 
acid (100 μM) or 1MCPC (100 μM) in Hutu-80 cells transfected with pCMV-FFAR2 or pCMV-eGFP. (e) 
Secretion relative to control of PYY (dark grey) or GLP-1 (light grey) by NCI-h716 pre-incubated with butyrate 
(2 mM) or TSA (500 nM) for 24 h, and subsequently incubated in non-stimulated conditions for 2 h; measured 
by ELISA. Mean basal secretion was 15.6 ± 1.6 pg/mL for PYY and 90.6 ± 4.3 pg/mL or GLP-1. Data are 
means ± s.e.m. of four distinct experiments. (***P < 0.001; **P < 0.01; *P < 0.05, Dunn to control test).
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Effect is specific to human tissues. As these cell lines have low expression of PYY and may not respond in 
the same way as EECs in vivo, we used primary intestinal epithelial cultures to validate these results. Incubation 
of human colonic primary cultures with SCFAs also increased the expression of PYY: butyrate and propionate 
increased expression ~16-fold and ~7-fold respectively, whereas acetate increased expression ~2-fold. Again, 
this effect was specific to PYY and no significant stimulation of GCG expression was observed (Fig. 3a). The 
main effect of propionate and butyrate appeared to be due to their HDAC inhibitory activity as TSA reproduced 
a similar effect. Qualitatively similar effects were also seen in primary cultures from human small intestine, but 
the magnitude of the stimulation was smaller (Fig. 3b). Similar to the NCI-h716 cells, human primary cultures 
incubated with butyrate or TSA for 24 h secreted more PYY but not GLP-1 when subsequently incubated in the 
absence of acute secretory stimulants. Preincubation with butyrate or TSA further increased acute PYY, but not 
GLP-1-secretory responses to the previously reported strong secretory cocktail of glucose, forskolin and IBMX7, 
demonstrating that increased PYY mRNA expression translated into increased secretory capacity (Fig. 3c and d).
Interestingly, SCFAs had no effect on Pyy gene expression in mouse colonic primary cultures (Fig. 3e). TSA 
also had no effect on Pyy expression despite increasing the expression of other genes known to be regulated by 
HDAC inhibition at the same concentration (Fig. 3f), indicating that mouse Pyy expression may not be regulated 
by HDAC inhibition in contrast to the observed responsiveness of human PYY. This motivated us to compare the 
PYY gene structure between the two species. Whereas the human PYY gene includes 4 non-translated 5′ exons 
spanning 50,000 bases (Fig. 3g), the murine Pyy sequence comprises only one non-translated 5′ exon. None of the 
three additional human exons had homology with the 5′ region of the mouse Pyy gene. We could find three GC 
boxes in the first 100 bases of the human promoter, domains recognized by SP1/SP3, that have been implicated 
in butyrate HDAC inhibitory effects16. No GC-boxes were apparent in the mouse Pyy proximal promoter or the 
human GCG promoter, which may explain why the effect of butyrate was limited to human PYY expression.
Discussion
Using human enteroendocrine cell lines, we characterized for the first time an important action of SCFAs, par-
ticularly propionate and butyrate, to increase PYY gene expression in human EECs. No changes were observed 
in transcription factors implicated in enteroendocrine cell number or differentiation, and the effect was specific 
to PYY but not GCG, although it should be noted that new EECs are not generated under our mixed primary 
culture conditions36 and that the human cell lines are a model of already EEC-committed cells32, leaving the 
possibility that in vivo increased differentiation of intestinal stem cells towards PYY and GLP-1 expressing cells 
might contribute to additional beneficial SCFA effects. The concentrations of SCFA we used are within the phys-
iological range observed in vivo in the colon and are high enough to fully stimulate both human and murine 
FFA2 and FFA3. Pharmacological activation of FFA2, but not FFA3 or GPR109a, induced a small increase of PYY 
expression, which seemed insufficient to account for the strong stimulation induced by propionate or butyrate. 
Importantly, a strong stimulation was preserved in FFA2 depleted cells. HDAC inhibitors, by contrast, reproduced 
the strong effect of butyrate and propionate on PYY expression, and butyrate increased the expression of other 
genes known to be regulated by HDAC inhibition in these cells17,37,38, confirming its activity as an HDAC inhibi-
tor in this model. We therefore concluded that HDAC inhibition likely explained the strong enhancement of PYY 
expression by propionate and butyrate. Interestingly, the strong stimulatory effect of SCFAs on PYY expression 
could be reproduced in human but not mouse primary intestinal cultures and TSA similarly only increased PYY 
expression in human tissues. We suggest that the difference between the two species reflects variation at the pro-
moter level. The presence of three SP1/SP3 binding GC boxes, which have been shown to be important elements 
in HDAC-regulated gene expression downstream of butyrate16, likely explain the selective stimulation of human, 
but not murine PYY-expression.
The increased expression of PYY mRNA resulted in higher secretion of PYY peptide, both under basal and 
stimulated conditions. SCFAs are therefore likely to increase PYY plasma levels both in fasted and fed states 
through this mechanism, and the pathway might contribute to the known long term effects of fibre-rich diets39 or 
prebiotics40 on PYY but not GLP-1 plasma levels due to the increased SCFA production through fibre fermenta-
tion. The effect we observed was concentration dependent and can therefore be considered as a mechanism capa-
ble of sensing microbial fermentation activity. SCFAs are also an energy source for the body and the described 
pathway can be considered as a way for the host to sense long term energy availability and correspondingly to 
adapt energy intake. However, as the different SCFAs did not induce identical responses, the ratio of their pro-
duction seems important. The relative production of different SCFAs is mainly controlled by the diet and the 
different types of fibre, as well as by the different bacterial species present in the gut microbiota. For example, 
obesity has been associated with a decreased number of butyrate and propionate producing bacterial species in 
favour of acetate producers41. Decreased gut concentrations of butyrate and propionate could therefore contribute 
to the decreased PYY levels seen in these patients through the mechanism presented here. Moreover, as PYY is 
known to regulate colonic motility and electrolyte secretion, modulating its biosynthesis and secretion may be an 
important way to regulate luminal contents and their concentrations. The pathway described here can be seen as 
a crosstalk between the gut microbiota and the host, in which bacterial metabolites regulate gut hormone levels 
that can in turn modulate the microbial environment.
Material and Methods
Cell culture and reagents. NCI-h716 cells (ATCC, CCL-251) and HuTu-80 cells (ATCC, HTB40) were 
maintained respectively in RPMI-1640 (Gibco, Life Technologies) and in EMEM (Sigma-Aldrich), all supple-
mented with 10% fetal bovine serum, 2 mM L-Glutamine, 50 IU/mL penicillin and 50 μg/mL streptomycin in a 
humidified incubator at 37 °C, 5% of CO2.
Primary cultures were prepared as already described7,36. Human tissues were obtained from Tissue Bank at 
Addenbrooke’s hospital, Cambridge, as approved by the local ethical review committee (09/H0308/24). All animal 
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Figure 3. Effect of SCFAs is species dependent. (a,b) Expression relative to untreated control cultures of PYY 
(dark grey) and GCG (light grey) in human colonic (a) and duodenal (b) cultures after incubation with SCFAs 
(2 mM) or TSA (500 nM). (c,d) Secretion, relative to control, of PYY (c) or GLP-1 (d) by colonic primary 
cultures pre-incubated with butyrate (2 mM) or TSA (500 nM) for 24 h, and subsequently incubated for 2 h 
in the absence of stimuli (dark grey) or in the presence of forskolin (10 μM), IBMX (10 μM) and glucose 
(10 mM) (light grey); measured by ELISA. Secretion is normalized to the protein content in the lysed cells, 
measured by BCA assay. Mean basal secretion was 0.42 pg/mL/μg of tissue and 0.019 pg/mL/μg of tissue for 
PYY and GLP-1, respectively. Analysis was performed comparing cells incubated with either butyrate or TSA 
to control-incubated cells, in both secretion conditions separately (***P < 0.001; **P < 0.01; *P < 0.05, Dunn 
to control test). (e) Expression of Pyy and Gcg in primary mouse colonic cultures after incubation with SCFAs 
(2 mM), relative to control-treated cultures. Data are means ± s.e.m. of four distinct experiments. (f) Effect 
of TSA (500 nM, 24 h) on the expression of genes known to be regulated by HDAC inhibition and on Pyy. 
(***P < 0.001; **P < 0.01; *P < 0.05, Dunn to control test). (g) Schematic representation of human and mouse 
PYY gene structure, indicating the exons and introns and highlighting the presence of GC boxes in the first 100 
bases of the promoter.
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procedures were approved by the University of Cambridge Animal Welfare and Ethical Review Body and con-
formed to the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039). The work was 
performed under the UK Home Office Project License 70/7824. Mice were sacrificed by cervical dislocation 
and intestinal tissue used in the experiments. Cleaned tissues were digested with collagenase type XI (0.5 mg/
mL for human tissue, 0.4 mg/mL for mouse tissue) and the crypt suspension plated into Matrigel coated plates 
and cultured for 24–48 h in DMEM 25 mM glucose supplemented with 10% FBS, 2mM L-Glutamine, penicillin, 
streptomycin and 1/1000 Y-27632 (Tocris).
Drugs and reagents were from Sigma-Aldrich. SCFAs, tiglic acid, 1-methylcyclopropane carboxylate 
(1-MCPC) and niacin were solubilized in water and pH adjusted between 7.2 and 7.4. Phorbol-12-myristate-
13-acetate (PMA), Trichostatin-A (TSA), Forskolin and isobutyl-1-methylxanthine (IBMX) were solubilized in 
DMSO; final concentration of DMSO had no detectable effect on cells.
Plasmid construction and transfection. Cloning of FFA2 was performed by PCR amplification 
from NCI-h716 genomic DNA and integrated after EcoRI and XhoI digestion into a pCMV-eGFP-N1 vector 
(a kind gift from A. Echard, Institut Pasteur, Paris). Oligonucleotides used for amplification of FFAR2 were 
5′-aaaactcgagatgctgccggactggaa-3′ and 5′-aaaagaattcctactctgtagtgaagtccga-3′. HuTu-80 cells were seeded at 2 × 105 
cells per well in 6-well plates 24 h before transfection. For transfection, medium was removed and replaced with 
Optimem (Gibco, Life Technologies) and 2 μg of plasmid DNA mixed with 4 μL lipofectamine 2000 (Invitrogen) 
in 50 μL Optimen were added following manufacturer’s instructions. Medium was replaced 6 h after transfection, 
and experiments were performed 24 to 48 h after transfection.
FFA2 depletion. Crispr/Cas9 was designed to specifically target FFAR2 coding sequence about 100 bases 
downstream of the start codon. Guide RNA (TGGCCCTGCGGGCCTTTGTGGGG) was integrated in a 
pX330-U6-Chimeric_BB-CBh-hSpCas9 vector containing guideRNA and Cas9 sequence, following published 
protocols (a gift from Feng Zhang, Addgene plasmid #42230)42. Clonal populations of transfected NCI-h716 
cells were selected based on their absence of response to SCFAs in calcium imaging, and gene disruption was 
confirmed by sequencing the region surrounding the targeted sequence by the RNA guide using the same oli-
gonucleotide as the ones used for FFAR2 cloning. FFAR3 sequence and expression was confirmed to remain 
unaltered. The oligonucleotide to amplify FFAR3 sequence were ATGGATACAGGCCCCGACCAG and 
CTAGCTTTCAGCACAGGCCAC, and sequencing was performed using nucleotides allowing a complete cov-
ering of the gene (CAGGCGGCTGTAGCAGTAGC and GGCCGAGGCTGGGGCAGGCA).
RNA extraction and qPCR. NCI-h716 (1 × 106 in 12-well plates) or HuTu-80 (5 × 105 in 6-well plates) 
cells were seeded 48 hours before lysis. Drugs were added 24 h before RNA extraction if not indicated otherwise. 
RNA was extracted using an RNeasy minikit with DNAse treatment (Qiagen). 2 μg of RNA were used for reverse 
transcription using High capacity cDNA Reverse transcription kit (Applied Biosystems). qPCRs were performed 
in duplicates on an AbiPrism 7000 system with Taqman gene expression assay probes (Supplementary Table S1) 
and Taqman gene expression master mix (LifeTechnologies). Data were analyzed using a 7000 System SDS soft-
ware (Applied Biosystems) and represented as the mean + -s.e.m. of the fold change of expression of at least three 
different experiments. Statistical analysis was performed on the fold change, using the Dunn to control test.
Secretion studies. For secretion studies, 4 × 105 NCI-h716 cells per condition were centrifuged and rinsed 
twice with saline buffer (NaCl 140 mM, KCl 5 mM, MgCl2 2 mM, CaCl2 2 mM, Hepes 10 mM, pH adjusted to 7.3). 
Human primary culture were rinsed twice with saline buffer. Cells were incubated 2 h in 200 μL of saline buffer 
with DiprotinA (30 mM) at 37 °C. Supernatant was centrifuged once and stored at −80 °C until used for ELISA. 
PYY and GLP-1 concentration in the supernatant of cell lines was measured using a total PYY and a total GLP-1 
Elisa kit (EZHPYYT66K and EZGLP1T-36K, Merck Millipore) using manufacturers’ instructions. Measurements 
were performed with a microplate reader (Infinite 2000, Tecan). GLP-1 and PYY measurement from primary 
cultures were performed by the Core Biochemical Assay Laboratory, Cambridge, UK using total GLP-1 and total 
PYY assays (MesoScale Discovery (MSD), Gaithersburg, MD, USA) and normalized to the total protein content 
of the lysed culture. Data was analyzed using R, presented as the fold change relative to the Control incubation/
Control stimulus and statistical analysis was assayed using the Dunn to control test, testing the effect of the incu-
bation independently to the secretion stimulus.
Data availability. No datasets were generated or analysed during the current study. Raw data and specific 
materials are available by contacting the corresponding author.
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